Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Uncontrolled Phase II-study to Investigate Pharmacokinetics, Safety and Biomarkers of Effectiveness of NeuroSTAT (Ciclosporin) in Patients With Severe Traumatic Brain Injury (TBI)

Trial Profile

An Open-label, Uncontrolled Phase II-study to Investigate Pharmacokinetics, Safety and Biomarkers of Effectiveness of NeuroSTAT (Ciclosporin) in Patients With Severe Traumatic Brain Injury (TBI)

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 04 Oct 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ciclosporin (Primary)
  • Indications Traumatic brain injuries
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Acronyms CHIC
  • Sponsors NeuroVive Pharmaceutical
  • Most Recent Events

    • 04 Oct 2018 According to a NeuroVive Pharmaceutical media release, biomarker analyses using samples from this study patients has been completed.
    • 04 Oct 2018 Results of biomarker analyses using samples from this study patients, presented in a NeuroVive Pharmaceutical media release.
    • 31 Aug 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top